1. |
Koretz RL, Stone O, Gitnick GL. The long-term course of non A,non B post-transfusion hepatitis. Gastroenterology, 1980, 79(5 Pt 1): 893-898.
|
2. |
Hartwell D, Shepherd J. Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis. Int J Technol Assess Health Care, 2009, 25(1): 56-62.
|
3. |
Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ, 2001, 323(7322): 1151-1155.
|
4. |
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
|
5. |
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
|
6. |
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
|
7. |
Hakozaki Y, Shirahama T, Katou M. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. The American journal of gastroenterology, 1995, 90(8): 1246-1249.
|
8. |
Bjoro K, Krarup H, Bell H. Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices. Scandinavian journal of gastroenterology, 1995, 30(11): 1119-1124.
|
9. |
Tassopoulos NC, Karvountzis G, Touloumi G. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. The American Journal of Gastroenterology, 1996, 91(9): 1734-1738.
|
10. |
Imai Y, Kawata S, Tamura S. Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study. Liver, 1997, 17(2): 88-92.
|
11. |
Ohmiya M, Hayashi J, Furusyo N. Large dose natural interferon alpha therapy for patients with chronic hepatitis C. Fukuoka Igaku Zasshi, 1997, 88(12): 380-388.
|
12. |
Piccinino F, Felaco FM, Sagnelli E. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment. Research in Virology, 1998, 149(5): 283-291.
|
13. |
姚光弼, 计焱焱. 两种剂量重组干扰素α2a治疗慢性丙型肝炎随机对照研究. 中华内科杂志, 1998, 37(2): 59-62.
|
14. |
Matsumoto A, Tanaka E, Suzuki T. Viral and host factors that contribute to efficacy of interferon-a2a therapy in patients with chronic hepatitis C. Dig Dis Sci, 1994, 39(6): 1273-1280.
|
15. |
Lin R, Roach E, Zimmerman M, et al. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol, 1995, 23(5): 487-496.
|
16. |
Hagiwara H, Hayashi N, Mita E. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology, 1993, 104(3): 877-883.
|
17. |
Chemello L, Bonetti P, Cavalletto L. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology, 1995, 22(3): 700-706.
|
18. |
Marcellin P, Pouteau M, Martinot-Peignoux M. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology, 1995, 109(1): 156-165.
|
19. |
Saracco G, Rosina F, Abate ML. Long term follow-up of patients with chronic hepatitis C Treated with different doses of interferon-a2b. Hepatology, 1993, 18(6): 1300-1305.
|
20. |
谢尧, 徐道振. HCV基因型对慢性丙型肝炎干扰素疗效的影响. 中华肝脏病杂志, 2004,12(2): 72-75.
|
21. |
金生, 周卫平. 丙型肝炎抗病毒治疗的影响因素及疗效预测. 中华肝脏病杂志, 2004, 12(2): 124-125.
|
22. |
Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis, 1995, 15(1): 82-91.
|